[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-cirrhosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-cirrhosis":25},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,96,0,25,[9,45,76,101,129,151,176,199,230,252,281,310,333,360,388,432,453,481,509,529,554,586,613,634,661],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100641359","intraoperative-assessment-of-microcirculatory-function-using-vascular-occlusion-test-during-liver-transplantation-100641359",false,"NCT07658794","Intraoperative Assessment of Microcirculatory Function Using Vascular Occlusion Test During Liver Transplantation","The Predictive Value of the Vascular Occlusion Test During Orthotopic Liver Transplantation for the Development of Early Allograft Dysfunction","Inclusion Criteria:\n\n* Adult patients aged 18 years or older\n* Patients scheduled to undergo orthotopic liver transplantation\n* Ability to obtain intraoperative Near-Infrared Spectroscopy measurements\n* Written informed consent obtained before enrollment\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Refusal or inability to provide informed consent\n* Emergency liver transplantation without sufficient time for enrollment\n* Inability to perform the Vascular Occlusion Test or obtain reliable NIRS measurements\n* Severe peripheral vascular disease or local upper-limb conditions interfering with monitoring","ALL",{"count":19,"type":20},50,"ESTIMATED","30 Days","OBSERVATIONAL","Early allograft dysfunction (EAD) remains one of the most important complications following orthotopic liver transplantation (OLT). Currently, there is no established intraoperative biomarker that reliably predicts graft dysfunction at an early stage. Near-infrared spectroscopy (NIRS) combined with the vascular occlusion test (VOT) is a non-invasive method for assessing tissue oxygenation and microcirculatory reserve. This prospective observational study aims to investigate whether VOT-derived parameters, including desaturation slope, recovery slope and post-ischemic hyperemic area under the curve (AUC-H), can predict EAD in liver transplant recipients. Measurements will be performed at four predefined intraoperative timepoints: after induction of anesthesia, during the anhepatic phase, during the neohepatic phase and at the end of surgery. The primary outcome is the occurrence of EAD according to Olthoff criteria.",[25,26],"Liver Cirrhosis","Early Allograft Dysfunction",[28,29,26,30,31],"Vascular Occlusion Test","Near-Infrared Spectroscopy","Liver Transplantation","Microcirculation","NOT_YET_RECRUITING","2026-06-27",{"date":35,"type":36},"2026-07-01","ACTUAL",{"date":38,"type":20},"2026-06",{"date":40,"type":20},"2027-06",{"name":42,"class":43},"Ippokrateio General Hospital of Thessaloniki","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100645405","phase-2-a-phase-2-study-of-foscenvivint-in-liver-cirrhosis-patients-caused-by-hivhcv-co-infection-with-hemophilia-100645405","NCT07681089","A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV\u002FHCV Co-infection With Hemophilia.","A Multicenter, Single-Arm, Open-Label Phase 2 Study of Once-Weekly Foscenvivint in Patients With Liver Cirrhosis Due to HIV\u002FHCV Co-infection in the Setting of Hemophilia.","OP-724-H202","Inclusion Criteria:\n\n* Patients with hemophilia and liver cirrhosis caused by HIV\u002FHCV co-infection who meet both of the following criteria:\n\n  1. Patients who are serum HIV-RNA positive or HIV antibody positive, with HIV-RNA maintained at \\\u003C200 copies\u002FmL and a CD4-positive T lymphocyte count of ≥200 cells\u002FµL at screening.\n  2. Patients with HCV infection who have achieved sustained virologic response (SVR) at least 12 months before registration.\n\n     * Patients with Child-Pugh class A or B liver cirrhosis (Child-Pugh score 5-9).\n     * Patients who meet at least one of the following criteria for the diagnosis of liver cirrhosis:\n\n  \u003C!-- -->\n\n  1. Liver stiffness measurement by FibroScan of ≥12.5 kPa, corresponding to fibrosis stage F4, at screening.\n  2. Abdominal CT showing changes in liver morphology and\u002For findings suggestive of portal hypertension.\n\n     * Patients with an Eastern Cooperative Oncology Group Performance Status of 0-2.\n\nExclusion Criteria:\n\n* Patients with liver cirrhosis caused by etiologies other than HCV or of unknown etiology.\n* Patients with esophageal or gastric varices judged by endoscopic examination at screening to require treatment.\n* Patients with current malignancy or a history of malignancy within 3 years before registration.\n* Patients who have undergone liver transplantation or other organ transplantation, including bone marrow transplantation.\n* Patients with active AIDS-defining disease requiring treatment. -","MALE","18 Years","79 Years",{"count":57,"type":20},4,"INTERVENTIONAL",[60],"PHASE2","This is a phase 2 study designed to evaluate the efficacy and safety of foscenvivint in patients with liver cirrhosis resulting from HIV\u002FHCV co-infection in the setting of hemophilia.",[25],[25,64,65],"Hemophilia","HIV\u002FHCV co-infection","2026-06-26",{"date":68,"type":36},"2026-07-02",{"date":70,"type":20},"2026-09-01",{"date":72,"type":20},"2028-03-31",{"name":74,"class":43},"Kiminori Kimura, MD",3,{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":58,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":100},"100617969","phase-2-a-study-to-test-whether-bi-3802876-is-tolerated-in-people-with-compensated-liver-cirrhosis-due-to-metabolic-dysfunction--associated-steatohepatitis-mash-100617969","NCT07325526","A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)","A Phase IIa Double-blind, Placebo-controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 3802876 in Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)","Inclusion Criteria :\n\n* Male or female adults ≥18 to ≤75 years of age at the time of screening, and at least the legal age of consent in countries where it is \\> 18 years\n* Patients meeting criteria for Child-Pugh category A without history of previous decompensation event\n* Compensated Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis diagnosed by 1 of the following:\n\n  * Biopsy (collected during screening or ≤ 5 years\\* prior to screening) showing cirrhosis (fibrosis stage 4) with steatosis or steatohepatitis.\n  * Biopsy (collected during screening or ≤ 5 years\\* prior to screening) showing cryptogenic cirrhosis.\n  * Biopsy showing steatosis or steatohepatitis prior to screening without confirmation of fibrosis stage 4, or current or previous imaging showing steatosis with no liver histology available must meet either one of the following inclusion criteria at screening:\n\n    1. Vibration-controlled transient elastography (VCTE) ≥ 15 kilopascals (kPa) plus 1 of the following, Magnetic Resonance Enterography (MRE) ≥4.2 kPa, platelet count \\\u003C150,000\u002FμL or imaging techniques (computed tomography (CT) scan and\u002For Magnetic Resonance Imaging (MRI) and\u002For Ultrasound) suggestive of cirrhosis.\n    2. VCTE measurement ≥ 20 kPa\n    3. Enhanced Liver Fibrosis (ELF) score ≥ 10.2 \\*If biopsy was collected \\> 365 days prior to screening either criteria a, b or c must be met Further inclusion criteria apply.\n\nExclusion Criteria :\n\n* Patients with clinically significant portal hypertension defined by any of the following:\n\n  * VCTE ≥25 kPa if the platelets are ≥150,000\u002FμL\n  * VCTE ≥20 kPa if platelets are \\\u003C150,000\u002FμL\n  * History of esophageal or gastric varices (Grade ≥1) on endoscopy\n  * ELF score ≥11.3\n  * Hepatic venous pressure gradient (HVPG) ≥10 mmHg\n* Other causes of liver disease based on medical history and\u002For centralized review of liver histology, including but not limited to alcoholic liver disease, autoimmune disorders (e.g., primary biliary cholangitis \\[PBC\\], primary sclerosing cholangitis \\[PSC\\], autoimmune hepatitis), drug-induced hepatotoxicity, Wilson disease, clinically significant iron overload, or alpha-1- antitryspin deficiency\n* Chronic viral hepatitis parameters that would be considered exclusionary for the participation in this trial are (hepatitis B and C testing will be done at screening visit):\n\n  * Hepatitis B virus (HBV): Past or present hepatitis B infection, including a positive hepatitis B surface antigen (HBsAg) and\u002For detectable HBV Deoxyribonucleic Acid (DNA).\n  * Hepatitis C virus (HCV): Past or present hepatitis C infection, including positive hepatitis C antibodies and\u002For detectable HCV ribonucleic acid (RNA).\n* History of liver transplantation or patients listed for liver transplantation\n* Suspicion, confirmed diagnosis, or history of Hepatocellular Carcinoma (HCC)\n* Present or past evidence of decompensating events of liver cirrhosis\n* Model for End-Stage Liver Disease (MELD) score \\> 12, unless due to therapeutic anti-coagulation\n* History of significant alcohol consumption (defined as intake of \\> 210 g\u002Fweek in males and \\> 140 g\u002Fweek in females on average over a consecutive period of more than 3 months) within 1 year prior to screening\n* International Normalized Ratio (INR) \\>1.3 unless due to therapeutic anticoagulants or laboratory error Further exclusion criteria apply.","75 Years",{"count":85,"type":20},29,[60],"This study is open to adults with a type of confirmed liver condition called compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH). The purpose of this study is to find out how well a study medicine called BI 3802876 is tolerated in people with this condition. The study looks at how different doses of BI 3802876 are handled by the body. BI 3802876 is being developed to improve liver health in people living with this liver condition.\n\nParticipants are put in 3 different dose groups randomly, which means by chance. Participants within a group get BI 3802876 or placebo. Placebo looks like BI 3802876 but does not contain any medicine. Participants have more than twice the chance of receiving BI 3802876 than placebo. The study medicine is given as an infusion into a vein.\n\nParticipants are in the study for about half a year. During this time, they visit the study site 12 times. At 2 visits, participants get the study medicine. Doctors collect information on any health problems and take blood samples to check how BI 3802876 is handled by the body. They compare results between the groups.",[25],"RECRUITING","2026-06-23",{"date":92,"type":36},"2026-06-24",{"date":94,"type":36},"2026-02-27",{"date":96,"type":20},"2027-10-17",{"name":98,"class":99},"Boehringer Ingelheim","INDUSTRY",27,{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":83,"enrollmentInfo":109,"targetDuration":4,"studyType":58,"phases":111,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":44},"100612423","comparison-of-underdilated-versus-standard-tips-in-preventing-variceal-rebleeding-in-patients-with-cirrhosis-100612423","NCT07253389","Comparison of Underdilated Versus Standard TIPS in Preventing Variceal Rebleeding in Patients With Cirrhosis","Comparison of Underdilated Versus Standard Transjugular Intrahepatic Portosystemic Shunt in Preventing Rebleeding From Esophagogastric Varices in Patients With Cirrhosis in Chinese Tertiary Hospitals: Protocol for a Multicenter Randomized Controlled Trial","UVR-TIPS","Inclusion Criteria:\n\n1\\. Age 18-75 years. 2. Diagnosis of liver cirrhosis according to the 2023 Consensus Opinion on the Clinical Diagnosis and Treatment of Liver Cirrhosis in China (Chinese Society of Gastroenterology). Diagnosis is based on clinical manifestations and imaging findings; histological confirmation is required if the diagnosis remains inconclusive.\n\n3\\. High-risk acute variceal bleeding, defined as any of the following:\n\n1. High-risk acute esophageal or type 1 gastroesophageal variceal bleeding, including: Child-Pugh grade B with a score \\> 7 and endoscopic evidence of active bleeding; Child-Pugh grade C with a score \\\u003C 14.\n2. Hepatic venous pressure gradient (HVPG) \\> 20 mmHg during bleeding.\n3. Early rebleeding within 5 days.\n4. Bleeding uncontrolled despite pharmacological and endoscopic therapy. 4. History of esophageal or gastric variceal bleeding with failure of standard first-line treatment \\[endoscopy combined with non-selective beta-blockers (NSBB)\\]; or first hemorrhage accompanied by grade 2 ascites and\u002For portal vein thrombosis; GOV2 or IGV1 gastric variceal bleeding; ectopic variceal bleeding; or bleeding from refractory portal hypertensive gastropathy.\n\n5\\. Planned TIPS procedure. 6. Ability and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n1. Budd-Chiari syndrome or other causes of non-cirrhotic portal hypertension.\n2. Current or prior malignancy, including hepatocellular carcinoma or malignancies of other organs.\n3. Complete thrombosis of the main portal vein.\n4. Severe psychiatric or neurologic disorders (e.g., uncontrolled epilepsy, dementia).\n5. Prior liver resection or liver transplantation.\n6. Prior TIPS or surgical portosystemic shunt.\n7. Pregnancy or lactation.\n8. Any contraindication to TIPS, including:\n\n(1) Congestive heart failure (New York Heart Association class C or D, or left ventricular ejection fraction \\\u003C 50%).\n\n(2) Severe pulmonary hypertension (mean pulmonary artery pressure \\> 45 mmHg as measured invasively).\n\n(3) Uncontrolled systemic infection. (4) Severe overt hepatic encephalopathy (OHE) with unmodifiable spontaneous portosystemic shunt.\n\n9.Acute hemorrhage with a MELD score ≥ 30 and\u002For arterial lactate \\> 12 mmol\u002FL, or presence of acute-on-chronic liver failure (ACLF).\n\n10\\. Systemic conditions requiring ongoing glucocorticoid or nonsteroidal anti-inflammatory drug (NSAID) therapy.",{"count":110,"type":20},648,[112],"NA","Transjugular intrahepatic portosystemic shunt (TIPS) is a key therapeutic intervention for complications of portal hypertension. However, the risk of post-procedural hepatic encephalopathy (HE) limits its broader clinical application. In the management of gastroesophageal variceal bleeding, the primary goal of TIPS is to reduce the portosystemic pressure gradient (PPG) to less than 12 mmHg (16 cmH₂O), which defines the standard TIPS procedure. The investigators hypothesize that, in patients undergoing TIPS for the prevention of variceal rebleeding, stent underdilation using a 6-mm balloon (underdilated TIPS) will not increase the risk of rebleeding but may reduce the incidence of overt HE and attenuate liver injury. To test this hypothesis, the investigators have designed a prospective, multicenter, randomized controlled trial.",[25,115],"Gastroesophageal Varices Bleeding",[25,117,118,119],"Esophageal and gastric variceal bleeding","Transjugular intrahepatic portosystemic shunt","Hepatic encephalopathy","2026-06-06",{"date":122,"type":36},"2026-06-09",{"date":124,"type":36},"2025-10-20",{"date":126,"type":20},"2029-09-30",{"name":128,"class":43},"Air Force Military Medical University, China",{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":135,"sex":17,"minAge":54,"maxAge":83,"enrollmentInfo":136,"targetDuration":138,"studyType":22,"phases":4,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":149,"locationsCount":44},"100639822","a-prospective-cohort-study-on-the-epidemiological-investigation-diagnosis-and-treatment-of-hepatic-encephalopathy-100639822","NCT07612670","A Prospective Cohort Study on the Epidemiological Investigation, Diagnosis, and Treatment of Hepatic Encephalopathy","Inclusion Criteria:\n\n* For patients with liver cirrhosis and the general healthy population, the diagnosis of liver cirrhosis is made by doctors based on imaging, elastography, biopsy or clinical symptoms.\n* The patients themselves and their accompanying family members have smart phones, are proficient in using WeChat and mini-programs, and have a stable network environment.\n* They voluntarily sign the informed consent form, have good compliance, and fully understand this study.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old;\n* Women planning to get pregnant, already pregnant or during lactation;\n* Incomplete relevant data information required;\n* Unable to proficiently use WeChat mini-program or unstable network environment;\n* Red-green color blindness or other irreparable visual impairments;\n* Heart, lung, or kidney failure or unstable vital signs;\n* Unwilling to participate in the study or unable to sign the informed consent form;\n* Any other situation that may interfere with the study assessment, increase the risk for the subjects, or affect their completion of the study, as judged by the researcher and deemed unsuitable for participating in this study;\n* Have participated in or are currently participating in other clinical trials within the past 3 months;",true,{"count":137,"type":20},700,"2 Years","Purpose Hepatic encephalopathy (HE) is a serious complication of liver cirrhosis that can cause memory loss, slow reaction, and even coma. In China, large-scale epidemiological data on HE are lacking, early diagnosis remains difficult, and treatment needs improvement. This study aims to investigate the prevalence of HE in Chinese liver disease patients and to explore better diagnostic methods and treatment strategies.\n\nDesign This is a prospective, multicenter cohort study led by Jiangsu Province Hospital, in collaboration with 7 other hospitals in Jiangsu Province. Between April 2026 and December 2029, the study plans to enroll over 700 patients with liver cirrhosis and 120 healthy volunteers.\n\nWhat participants will do Participants will use a WeChat mini-program to perform simple cognitive tests (e.g., reaction speed, attention) regularly. They will be followed up at month 1, 3, 6 after enrollment, and then every six months. The research team will collect routine laboratory results, medication records, and quality-of-life data.\n\nBenefits and risks Participants will receive closer health monitoring, which may help detect changes early. The study involves no additional drugs or invasive procedures, so risks are very low. All personal information will be kept strictly confidential and used only for medical research.\n\nVoluntary participation Participation is completely voluntary, and participants can withdraw at any time without affecting their routine medical care.",[141,142,25],"Hepatic Encephalopathy","Minimal Hepatic Encephalopathy","2026-05-24",{"date":145,"type":36},"2026-05-29",{"date":147,"type":20},"2026-06-01",{"date":72,"type":20},{"name":150,"class":43},"The First Affiliated Hospital with Nanjing Medical University",{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":159,"targetDuration":161,"studyType":22,"phases":4,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":175},"100640745","austrian-pbc-registry-100640745","NCT07598669","Austrian PBC Registry","Characterisation of Patients With Primary Biliary Cholangitis in Austria - A Prospective Registry and Biobank","PBC-AUT","Inclusion Criteria:\n\n* Age \\>18 years\n* Confirmed diagnosis of primary biliary cholangitis (at least two of the following three criteria must be fulfilled: persistent elevation of alkaline phosphatase above the upper limit of normal for at least 6 months; presence of antimitochondrial antibodies or PBC-specific antinuclear antibodies; characteristic histopathology)\n* Written informed consent for participation in the registry\n\nExclusion Criteria:\n\n* Withdrawal of written informed consent",{"count":160,"type":20},500,"10 Years","The goal of this registry is to better understand how primary biliary cholangitis develops over time, including the role of disease-related biomarkers, complications of the disease, and symptom burden. Patients with primary biliary cholangitis treated at participating centres in Austria will be invited to take part in this prospective registry. Participation in an associated biobank is optional. Clinical and laboratory data will be collected, and patients will be followed regularly through scheduled clinic visits. In addition, biological samples (serum, plasma, and, if available, liver tissue) may be collected and stored in the biobank for future research.",[164,25,165],"Primary Biliary Cholangitis","Portal Hypertension","2026-05-16",{"date":168,"type":36},"2026-05-20",{"date":170,"type":36},"2026-03-18",{"date":172,"type":20},"2040-12",{"name":174,"class":43},"Medical University of Vienna",11,{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":83,"enrollmentInfo":184,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":186,"conditions":187,"keywords":188,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":195,"leadSponsor":197,"locationsCount":44},"100630648","long-term-efficacy-and-safety-of-lsd-versus-tips-for-cirrhotic-portal-hypertension-bleeding-and-hypersplenism-100630648","NCT07490405","Long-term Efficacy and Safety of LSD Versus TIPS for Cirrhotic Portal Hypertension Bleeding and Hypersplenism","Long-term Efficacy and Safety of Laparoscopic Splenectomy and Azygoportal Disconnection Versus Transjugular Intrahepatic Portosystemic Shunt for Cirrhotic Portal Hypertension With Acute Esophagogastric Variceal Bleeding and Hypersplenism","LSD、TIPS","Inclusion Criteria:\n\n1. Confirmed diagnosis of cirrhotic portal hypertension.\n2. Endoscopic examination confirmed the presence of severe esophagogastric varices accompanied by acute bleeding. Rebleeding occurred after endoscopic variceal ligation (EVL) treatment..\n3. Presence of hypersplenism causing significant thrombocytopenia and\u002For leukopenia.\n4. Liver function Child-Pugh class A or B (score 7-9).\n5. Age 18-75 years.\n6. Patient provides written informed consent.\n\nExclusion Criteria:\n\n1. Liver function Child-Pugh class C (score ≥10), or Model for End-Stage Liver Disease (MELD) score \\>18.\n2. Severe right heart failure or pulmonary hypertension.\n3. Uncontrolled systemic infection or sepsis.\n4. Polycystic liver disease, portal cavernous transformation, or portal vein thrombosis (affecting procedure or shunt creation).\n5. Advanced hepatocellular carcinoma (beyond Milan criteria) or other uncontrolled malignancies.\n6. Severe hepatic encephalopathy (West-Haven grade III-IV) unresponsive to medication.\n7. Severe contrast agent allergy (affecting TIPS procedure).\n8. Pregnancy or lactation.\n9. Any severe non-hepatic disease with a life expectancy \\\u003C1 year.\n10. Recent gastric and duodenal ulcers.\n11. Inability to comply with follow-up or provide informed consent.",{"count":185,"type":20},140,"This study aims to compare two treatments for cirrhotic portal hypertension with acute esophagogastric variceal bleeding and hypersplenism: laparoscopic splenectomy and azygoportal disconnection (LSD) and transjugular intrahepatic portosystemic shunt (TIPS). It is a single-center, prospective trial. The primary outcome is the incidence of post-procedure hepatic encephalopathy. Secondary outcomes include changes in hepatic venous pressure gradient, portal and hepatic artery hemodynamics, liver function, renal function, complete blood count, immune function, hepatic reserve capacity, serological markers of liver fibrosis, re-bleeding rate, hepatocellular carcinoma incidence, recompensation incidence, overall survival, and bleeding-free survival. The study will provide high-level evidence for optimal treatment selection in this patient population.",[25],[25,189,190],"LSD","TIPS","2026-05-14",{"date":193,"type":36},"2026-05-18",{"date":147,"type":20},{"date":196,"type":20},"2036-04-01",{"name":198,"class":43},"Northern Jiangsu People's Hospital",{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":209,"conditions":210,"keywords":213,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":229},"100640555","establishing-a-reference-framework-for-outcomes-after-machine-preserved-liver-transplantation-in-europe-100640555","NCT07585890","Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe","Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe (REFRAME-MP)","REFRAME-MP","Inclusion Criteria:\n\n* All postmortal livers accepted (transplanted and not-transplanted after machine perfusion) upon organ offer for patients \\>18 years at the time of liver transplantation.\n* All donor types (DBD, DCD)\n* Preservation either with static cold storage alone or combined with machine perfusion (MP).\n* Donor livers underwent MP as part of routine clinical practice and the choice of perfusion protocol was made according to institutional standard practice.\n* Eligible MP protocols are:\n\n  1. end-ischemic single- or dual hypothermic oxygenated MP \\[e(D)HOPE\\],\n  2. end-ischemic (back-to-base) normothermic MP \\[eNMP\\],\n  3. continuous (device-to-donor) normothermic MP \\[cNMP\\],\n  4. e(D)HOPE followed by controlled oxygenated rewarming and normothermic MP \\[e(D)HOPE-COR-NMP)\\],\n  5. e(D)HOPE followed by normothermic MP \\[e(D)HOPE-NMP\\], or\n  6. Normothermic regional perfusion followed by SCS or an ex situ MP protocol.\n* A minimum follow-up of 12 months after liver transplantation is required.\n\nExclusion Criteria:\n\n* Livers that were allocated to a MP protocol as part of a prospective randomized or interventional clinical trial comparing different preservation techniques or any other invention.\n* Living donor liver transplantation",{"count":208,"type":20},10000,"Machine perfusion (MP) has become routine clinical practice in liver transplantation. However, as the field has matured, direct randomized comparisons between distinct MP modalities have become increasingly impractical, given that donor and graft characteristics often predetermine the optimal preservation strategy. Consequently, many studies continue to reference historical benchmark cohorts from the pre-perfusion era, or use risk scores developed before routine utilization of MP. These cohorts, while once valuable, fail to account for the paradigm shift that MP has introduced. Likewise, commonly used donor- and recipient-based risk scores were developed prior to the adoption of MP. While these scores aim to assess survival or morbidity after transplantation, none of them guide decisions about MP use or the most suitable perfusion protocol. As MP technologies continue to evolve there is a critical need for an updated reference framework that accurately reflects current clinical practice and captures the best achievable outcomes across all MP modalities.",[211,212,25,30],"End-stage Liver Disease (ESLD)","Acute Liver Failure",[214,215,216,217,218,219,220],"machine perfusion","liver transplantation","hypothermic machine perfusion","normothermic machine perfusion","normothermic regional perfusion","organ preservation","machine preservation","2026-05-11",{"date":191,"type":36},{"date":224,"type":36},"2026-04-21",{"date":226,"type":20},"2030-12-31",{"name":228,"class":43},"University Medical Center Groningen",2,{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":58,"phases":240,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":44},"100640330","sonazoid-ceus-for-early-hcc-surveillance-100640330","NCT07590284","Sonazoid CEUS for Early HCC Surveillance","A Multicenter, Prospective Study of Sonazoid CEUS for Early HCC Surveillance in a High-risk Population","Inclusion Criteria:\n\n1. Cirrhotic patients diagnosed clinically or radiologically due to any etiology (patients with cirrhosis due to congenital fibrosis and patients with cirrhosis due to vascular causes were excluded).\n2. Age 18-80 years old.\n3. Able to receive regular imaging, including US, CEUS, and CECT or CEMRI or EOB-MRI, according to the diagnostic and treatment procedures.\n4. Obtained informed consent from the patient.\n\nExclusion Criteria:\n\n1. Patients with pathologic or enhanced imaging of established HCC who have not undergone curative treatment.\n2. Patients with known hypersensitivity to enhanced imaging contrast agents.\n3. Patients with severe cardiac, pulmonary or renal insufficiency that precludes CECT or CEMRI or EOB-MRI.\n4. Lactating and pregnant women.\n5. Those who are not suitable for enrollment as assessed by the investigator.\n6. Patients with egg or egg-product allergy, or with severe right-to-left cardiac shunt or intrapulmonary shunt.","80 Years",{"count":239,"type":20},556,[112],"This study is a multicenter, prospective study. In this study, enrolled subjects are cirrhotic patients of any etiology. The US and Sonazoid CEUS monitoring strategy was performed for cirrhotic patients: US and AFP joint with Sonazoid CEUS every 4 to 6 months, and combined CECT\u002FCEMRI every 12 months.",[25,243],"Liver Fibrosis",{"date":245,"type":36},"2026-05-15",{"date":247,"type":20},"2026-05-30",{"date":249,"type":20},"2029-12-30",{"name":251,"class":43},"Tianjin Third Central Hospital",{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":83,"enrollmentInfo":260,"targetDuration":4,"studyType":58,"phases":262,"briefSummary":263,"conditions":264,"keywords":266,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":75},"100639849","underdilated-vcx-tips-versus-evl-plus-nsbb-for-secondary-prophylaxis-of-variceal-bleeding-in-cirrhosis-100639849","NCT07587671","Underdilated VCX-TIPS Versus EVL Plus NSBB for Secondary Prophylaxis of Variceal Bleeding in Cirrhosis","Underdilated VIATORR Controlled Expansion Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Variceal Ligation Plus Nonselective Beta-Blockers for Secondary Prophylaxis of Variceal Bleeding in Patients With Cirrhosis: A Multicenter, Open-Label, Randomized Controlled Trial","U-TIPS","Inclusion Criteria:\n\n* Age 18 to 75 years, regardless of sex.\n* Diagnosis of liver cirrhosis based on previous histology, imaging, laboratory tests, and\u002For clinical manifestations.\n* Hospitalization for acute upper gastrointestinal bleeding, with endoscopic confirmation that the bleeding is related to esophageal varices or type 1 gastroesophageal varices.\n* Successful control of acute bleeding after standard acute-phase treatment, with stable vital signs and entry into the secondary prophylaxis phase.\n* Child-Pugh score of 5 to 13.\n* The investigator judges that both underdilated VCX-TIPS and EVL plus NSBB are clinically feasible and that randomization is appropriate.\n* The participant or legally authorized representative understands the study procedures and voluntarily signs written informed consent.\n\nExclusion Criteria:\n\n* Hemodynamic instability, persistent active bleeding, or need for immediate rescue TIPS, surgical hemostasis, or interventional radiologic hemostasis.\n* A strong current indication for early or pre-emptive TIPS that makes randomization to EVL plus NSBB clinically inappropriate.\n* Child-Pugh score greater than 13.\n* Previous TIPS, surgical portosystemic shunt, BRTO, CARTO, PARTO, or other procedures that substantially alter portosystemic blood flow.\n* Isolated gastric varices, type 2 gastroesophageal varices, ectopic varices, or a bleeding source other than esophageal varices or type 1 gastroesophageal varices.\n* Non-cirrhotic portal hypertension.\n* Cavernous transformation of the portal vein or portal venous thrombosis that makes standardized TIPS technically infeasible.\n* Previous recurrent or refractory overt hepatic encephalopathy, or a history of West Haven grade II to IV overt hepatic encephalopathy unrelated to gastrointestinal bleeding.\n* Severe heart failure, severe pulmonary hypertension, severe tricuspid regurgitation, right heart failure, or other contraindications to TIPS.\n* Uncontrolled severe infection, sepsis, or multiple organ failure.\n* Hepatocellular carcinoma beyond the Milan criteria or other advanced malignancy.\n* Severe renal insufficiency requiring long-term renal replacement therapy.\n* Pregnancy or breastfeeding.\n* Absolute contraindication to EVL, NSBB, or TIPS.\n* Any condition that, in the investigator's judgment, makes the participant unsuitable for the study or unable to complete follow-up.",{"count":261,"type":20},240,[112],"Variceal bleeding is a major complication of portal hypertension in patients with cirrhosis and is associated with substantial risks of rebleeding and death. Current guidelines recommend endoscopic variceal ligation combined with nonselective beta-blockers as standard secondary prophylaxis for esophageal variceal bleeding and type 1 gastroesophageal variceal bleeding. Transjugular intrahepatic portosystemic shunt can markedly reduce portal pressure and prevent recurrent variceal bleeding, but its broader use in secondary prophylaxis is limited by the risk of post-TIPS hepatic encephalopathy and liver function deterioration.\n\nThe VIATORR Controlled Expansion stent is designed to allow controlled expansion between 8 and 10 mm. However, even 8-mm TIPS may still be associated with a substantial risk of overt hepatic encephalopathy. This trial evaluates an underdilated VCX-TIPS strategy, in which a commercially available 8-10 mm VIATORR Controlled Expansion stent is initially dilated only with a 6-mm balloon, aiming to achieve sufficient portal decompression while reducing the risk of excessive shunting.\n\nThis is a prospective, multicenter, open-label, parallel-group, randomized superiority trial. Eligible patients with cirrhosis who have recovered from acute esophageal variceal bleeding or type 1 gastroesophageal variceal bleeding and have entered the secondary prophylaxis phase will be randomly assigned in a 1:1 ratio to receive either underdilated VCX-TIPS or endoscopic variceal ligation plus nonselective beta-blockers. The primary outcome is the composite of all-cause death or clinically significant upper gastrointestinal rebleeding within 1 year after randomization.",[25,165,115,265,141],"Esophageal Varices",[267,268,269,270,118,271,272,119],"Cirrhosis","Portal hypertension","Esophageal variceal bleeding","Secondary prophylaxis","Underdilation","Endoscopic variceal ligation","2026-05-07",{"date":191,"type":36},{"date":276,"type":20},"2026-08-01",{"date":278,"type":20},"2030-07-30",{"name":280,"class":43},"West China Hospital",{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":290,"conditions":291,"keywords":296,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":4},"100636914","ultrasound-prediction-of-esophageal-variceal-bleeding-risk-100636914","NCT07571876","Ultrasound Prediction of Esophageal Variceal Bleeding Risk","Splenic Size and Portal Vein Diameter on Ultrasound in Predicting Esophageal Variceal Bleeding Risk","Inclusion Criteria:\n\n* Adult patients (age ≥18 years) with chronic liver disease and clinical\u002Flaboratory\u002Fradiological evidence of liver cirrhosis\n* Both compensated and decompensated cirrhosis (Child-Pugh classes A, B, and C)\n* Patients scheduled for upper gastrointestinal endoscopy\n* Patients who provide informed consent\n\nExclusion Criteria:\n\n* Previous history of endoscopic variceal band ligation or sclerotherapy\n* Prior surgical portosystemic shunt procedures or transjugular intrahepatic portosystemic shunt (TIPS)\n* Hepatocellular carcinoma with portal vein thrombosis\n* Previous splenectomy\n* Patients receiving beta-blockers for variceal bleeding prophylaxis\n* Poor quality ultrasound images due to obesity or ascites\n* Refusal to participate in the study",{"count":289,"type":20},165,"This prospective observational study aims to evaluate the accuracy of using routine abdominal ultrasound to predict the risk of esophageal variceal bleeding in adult patients with liver cirrhosis. Esophageal variceal bleeding is a serious complication of chronic liver disease. While upper gastrointestinal endoscopy is the current standard for diagnosing and grading these varices, it is an invasive procedure.\n\nIn this study, researchers will use ultrasound to measure the patient's spleen size and portal vein diameter. These non-invasive measurements will then be compared to the results of a standard upper endoscopy performed within 48 to 72 hours. The goal is to determine if these simple ultrasound measurements can reliably predict the presence, grade, and bleeding risk of esophageal varices, which could potentially reduce the need for routine invasive endoscopic screenings in the future.",[292,293,294,265,25,165,295],"Variceal Bleeding","Ultrasonography","Esophageal Bleeding","Chronic Liver Disease (CLD)",[297,298,299,300],"portal vein diameter","splenic size","ultrasound","esophageal variceal bleeding risk","2026-05-04",{"date":303,"type":36},"2026-05-06",{"date":305,"type":20},"2026-04",{"date":307,"type":20},"2027-05",{"name":309,"class":43},"Assiut University",{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":316,"targetDuration":4,"studyType":58,"phases":318,"briefSummary":319,"conditions":320,"keywords":322,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":44},"100604620","the-diagnostic-value-of-subharmonic-imaging-technology-combined-with-liver-stiffness-and-platelet-count-for-high-risk-esophageal-and-gastric-varices-in-patients-with-liver-cirrhosis-100604620","NCT07151885","The Diagnostic Value of Subharmonic Imaging Technology Combined With Liver Stiffness and Platelet Count for High-risk Esophageal and Gastric Varices in Patients With Liver Cirrhosis","Inclusion Criteria:\n\n* ① Be at least 18 years old② Clinically diagnosed as liver cirrhosis (based on medical history, physical signs, laboratory tests, imaging or liver biopsy)③ Underwent a gastroscopy④ The informed consent form has been signed\n\nExclusion Criteria:\n\n* ① Previous EV bleeding or having received TIPS\u002F endoscopic treatment.② History of concurrent liver cancer, portal vein thrombosis, and splenectomy.③ Having used drugs that affect platelet count, liver function or coagulation function in the body within one week, and having a recent history of blood product infusion.",{"count":317,"type":20},380,[112],"To evaluate the diagnostic value of the combined model of subharmonic-assisted pressure estimation (SHAPE), liver stiffness (LSM), and platelet count (PLT) for high-risk esophageal and gastric varices (HRV)",[25,321],"Esophageal and Gastric Varices",[25,321,323],"Subharmonic Aided Pressure Estimation","2026-04-29",{"date":326,"type":36},"2026-05-05",{"date":328,"type":36},"2025-08-31",{"date":330,"type":20},"2028-07-31",{"name":332,"class":43},"The First Hospital of Jilin University",{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":237,"enrollmentInfo":341,"targetDuration":4,"studyType":58,"phases":343,"briefSummary":344,"conditions":345,"keywords":347,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":44},"100560422","early-tips-in-patients-with-liver-cirrhosis-and-ascites-100560422","NCT06576934","Early TIPS in Patients With Liver Cirrhosis and Ascites","Early Implantation of a Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Patients With Liver Cirrhosis and Ascites: a Multicentre, Randomised Controlled Trial","eTIPS","Inclusion Criteria:\n\nPatients eligible for inclusion in this trial must meet all of the following criteria:\n\n1. Patients ≥ 18 years and \\\u003C 80 years\n2. Liver cirrhosis as documented by previous liver biopsy or by a combination of typical clinical, biochemical and sonographic features\n3. Ascites as the first single decompensating event with grade 2 ascites and MELD ≥ 15 OR grade 3 ascites\n4. INR ≤ 1.5\n5. Ability to understand the nature of the trial and the trial related procedures and to comply with them\n\nExclusion Criteria:\n\nPatients eligible for this trial must not meet any of the following criteria:\n\n1. Treatment refractory or recurrent ascites at the time of study inclusion\n2. Patients with concomitant variceal bleeding fulfilling the criteria for pre-emptive TIPS implantation (Child-Pugh class C \\\u003C 14 points or Child-Pugh class B \\>7 with active bleeding at initial endoscopy or hepatic venous pressure gradient \\[HVPG\\] \\> 20 mmHg at the time of bleeding)\n3. Budd-Chiari syndrome\n4. Portal vein thrombosis (PVT)\n5. Spontaneous bacterial peritonitis (SBP)\n6. Uncontrolled systemic infection (defined as an increase of \\> 20% if inflammatory parameters \\[C-reactive protein, procalcitonin, leukocytes\\] and\u002For sepsis as a reason for development of ascites\n7. Cardiac cirrhosis (defined as the development of liver cirrhosis in a patient with cardiac heart failure due to primary cardiac disease)\n8. Clinical significant cardiac disease (NYHA ≥II)\n9. Untreated valvular heart disease: middle to high-grade valve stenosis or insufficiency (applies to mitral, tricuspid, aortic and pulmonary valves)\n10. Diastolic dysfunction grade III, stated by transthoracic echocardiogram (TTE)\n11. Reduced left ventricular ejection fraction ≤50%\n12. Pulmonary hypertension (mean pulmonary arterial pressure \\> 45 mmHg)\n13. Bilirubin \\> 3 mg\u002Fdl\n14. Obstructive cholestasis\n15. Hepatorenal syndrome type AKI (HRS-AKI)\n16. Acute on chronic liver failure\n17. Benign liver tumor within the potential puncture tract\n18. Patient after liver transplantation\n19. Prior TIPS implantation\n20. Ongoing and\u002For recurrent hepatic encephalopathy (grade \\>II)\n21. Active tumor disease including hepatocellular carcinoma defined as need for chemotherapy, radiation therapy, interventional or surgical treatment\n22. New onset of antiviral treatment for chronic hepatitis B virus (HBV) infection within the last 3 months\n23. Untreated chronic hepatitis C virus (HCV) infection\n24. Life expectancy \\\u003C1 year\n25. Pregnant or breastfeeding women\n26. Patients without the legal capacity who are unable to understand the nature, significance and consequences of the study\n27. Simultaneous participation in other interventional trials which could interfere with this trial; simultaneous participation in registry and diagnostic trials is allowed\n28. Person who is in a relationship of dependence\u002Femployment with the sponsor or the investigator",{"count":342,"type":20},134,[112],"The aim of this clinical trial is to compare the safety and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) implantation with standard treatment (diuretic medications, and if necessary, paracenteses) in patients with liver cirrhosis and development of ascites as the first decompensating event.\n\nBy creating a shunt between the liver vein and the portal vein, blood is diverted from the portal vein directly into the hepatic vein, which results in a reduction of pressure in the portal vein so that development of ascites is reduced.",[25,346,165],"Ascites Hepatic",[348,118,349,350],"liver cirrhosis","ascites","MELD","2026-04-27",{"date":353,"type":36},"2026-05-01",{"date":355,"type":36},"2025-04-01",{"date":357,"type":20},"2029-02-15",{"name":359,"class":43},"University Hospital Freiburg",{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":368,"enrollmentInfo":369,"targetDuration":371,"studyType":22,"phases":4,"briefSummary":372,"conditions":373,"keywords":378,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":382,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":44},"100499384","freiburg-tips-registry-100499384","NCT05782556","Freiburg TIPS Registry","Transjugular Intrahepatic Portosystemic Shunt (TIPS) for the Treatment of Portal Hypertension: an Observational Study","FRETIR","Inclusion Criteria:\n\n* Patients allocated to TIPS implantation due to clinically significant cirrhotic and non-cirrhotic portal hypertension\n\nExclusion Criteria:\n\n* Withdrawal of written informed consent","100 Years",{"count":370,"type":20},2000,"12 Months","Patients with clinically significant portal hypertension allocated to implantation of a transjugular intrahepatic portosystemic shunt (TIPS) at the Department of Medicine II of the University Medical Center Freiburg, Germany will be offered to participate in this prospective observational trial.\n\nClinical and laboratory as well as outcome parameters will be assessed before and within the first 12 months after TIPS implantation following a regular follow-up schedule with clinical visits at the University Medical Center Freiburg. During follow-up visits, serum\u002Fplasma samples and peripheral blood mononuclear cells (PBMC) are collected and stored in a associated biobank.",[25,165,374,375,376,377],"Non-Cirrhotic Portal Hypertension","Budd Chiari Syndrome","Portal Vein Thrombosis","Portal Systemic Shunt",[379,118,374,380,381],"Liver cirhosis","Prognosis","Outcome",{"date":353,"type":36},{"date":384,"type":36},"2023-01-01",{"date":386,"type":20},"2034-06-30",{"name":359,"class":43},{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":394,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":396,"enrollmentInfo":397,"targetDuration":4,"studyType":58,"phases":399,"briefSummary":400,"conditions":401,"keywords":406,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":229},"100636088","nutrition-and-exercise-prehabilitation-in-patients-awaiting-liver-transplantation-100636088","NCT07561138","Nutrition and Exercise Prehabilitation in Patients Awaiting Liver Transplantation","Evaluation of Protein Distribution Optimization With Exercise Regimen on Nutritional Status, Body Composition and Functional Status in Patients Awaiting Liver Transplantation: The POWER-LT Randomized Clinical Trial","POWER-LT","Inclusion Criteria:\n\n* End-stage liver disease, diagnosed by transient elastography (FibroScan) or imaging-based evaluation with compatible clinical picture\n* Referred for liver transplantation and evaluated to have a high likelihood of being listed, according to primary hepatologist assessment, or already listed for liver transplantation\n* No prior formal dietary advice\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old\n* Estimated waiting time for liver transplantation \\\u003C 3 months\n* Estimated life expectancy \\\u003C 3 months\n* Chronic kidney disease requiring protein restriction\n* Exercise contraindicated (e.g., active or recent variceal bleeding, severe grade of hepatic encephalopathy, refractory ascites, etc.)\n* Unstable or severe psychiatric disorder\n* Pregnancy or lactation\n* Inability to provide written informed consent","70 Years",{"count":398,"type":20},90,[112],"This study aims to evaluate the effects of a diet with even protein distribution plus exercise (Group A) versus a diet with skewed protein distribution plus exercise (Group B) versus standard dietary and physical activity advice (Group C) on nutritional status, body composition and functional status in patients awaiting liver transplantation.",[402,25,30,403,404,405],"End-stage Liver Disease","Malnutrition","Sarcopenia","Frailty",[407,408,348,215,409,410,411,412,413,414,415,416,417,418,419,420,421,422,423],"liver disease","end-stage liver disease","malnutrition","sarcopenia","frailty","diet","nutrition","nutrition therapy","protein","protein distribution","exercise","prehabilitation","nutritional status","body composition","functional status","physical performance","quality of life","2026-04-24",{"date":353,"type":36},{"date":427,"type":36},"2026-01-08",{"date":429,"type":20},"2029-07",{"name":431,"class":43},"Kalliopi Anna Poulia",{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":439,"targetDuration":4,"studyType":58,"phases":441,"briefSummary":442,"conditions":443,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":449,"leadSponsor":451,"locationsCount":44},"100635528","endoscopic-shunts-embolization-for-refractory-hepatic-encephalopathy-100635528","NCT07553858","Endoscopic Shunts Embolization for Refractory Hepatic Encephalopathy","Endoscopic Ultrasound Embolization of Porto-Systemic Shunt for Management of Medically Refractory Hepatic Encephalopathy: A Randomized Trial","Inclusion Criteria:\n\n1. Adults aged ≥18 years with known cirrhosis\n2. MRHE; defined as ≥2 episodes of hepatic encephalopathy, HE (as documented in an outpatient office visit or during an inpatient admission) within 6 months prior to enrollment despite medical therapy with lactulose and rifaximin\n3. Admission to inpatient hepatology floor at University Hospital-Newark with MRHE at the time of enrollment\n4. Presence of a spontaneous portosystemic shunt; confirmed on CT\u002FMRI at the index admission.\n\nExclusion Criteria:\n\n1. Severe\u002Frefractory ascites defined as ascites that does not recede after medical therapy or reoccurs shortly after fluid has been removed\n2. Refractory or recurrent bleeding from esophageal varices\n3. Presence of portal vein thrombosis with complete occlusion\n4. Hepatocellular carcinoma beyond Milan criteria or other advanced malignancy with limited life expectancy (\\\u003C6 months)\n5. Platelet count of less than 35,000 and\u002For INR of more than 2 which cannot be corrected for the EUS guided embolization procedure.\n6. Hepatic venous occlusion, or right heart failure as the etiology of cirrhosis.",{"count":440,"type":20},34,[112],"The goal of this clinical trial is to learn if endoscopic ultrasound guided (EUS guided) spontaneous porto-systemic shunt (SPSS) embolization works to treat refractory hepatic encephalopathy in adults. It will also learn about the safety of EUS guided embolization. The main questions it aims to answer are:\n\n1. Does EUS guided embolization maintain an acceptable safety profile?\n2. Does EUS guided embolization of large SPSS result in significant clinical improvement in patients with refractory hepatic encephalopathy?\n\nParticipants will:\n\n1. Receive EUS guided embolization or medical management.\n2. Receive follow-up EUS procedures one month after embolization for assessment of the shunt patency and development of varices (embolization group).\n3. Receive follow-up every week for 4 weeks to assess degree of worst episode of hepatic encephalopathy via West Haven criteria.",[141,25,444],"Portal Shunt Systemic","2026-04-20",{"date":447,"type":36},"2026-04-28",{"date":353,"type":20},{"date":450,"type":20},"2028-11-01",{"name":452,"class":43},"Rutgers, The State University of New Jersey",{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":457,"acronym":458,"eligibilityCriteria":459,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":460,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":462,"conditions":463,"keywords":464,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":474,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":44},"100626769","exploration-of-systemic-and-portal-hemostasis-in-patients-undergoing-transjugular-intrahepatic-portosystemic-shunt-placement-100626769","NCT07439939","Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Placement","PORTHEMOST","Inclusion Criteria:\n\n* Adult patients (aged ≥18 years) covered by a social security scheme or entitled beneficiaries\n* Patients followed for a cirrhotic condition at Paul Brousse Hospital and undergoing placement of a TIPS (transjugular intrahepatic portosystemic shunt)\n\nExclusion Criteria:\n\n* Patient unwilling to participate in the study\n* Patient with a contraindication to TIPS placement\n* Patient with a known hemostatic disorder unrelated to cirrhosis\n* Patient receiving treatment that interferes with hemostasis and has not been discontinued for the procedure\n* Patient receiving systemic corticosteroid therapy\n* Patient under legal protection\n* Patient not covered by a social security scheme",{"count":461,"type":20},45,"Portal vein thrombosis is defined as non-tumoural obstruction of the portal vein or one of its branches. Its incidence is 0.7 to 2.7 per 100,000 patient-years in the general population, and 4.6 per 100 patient-years in patients with cirrhosis. Histological modificaitions fo the portal vein wall and haemostatic changes have been described in cirrhotic patients. The contribution of these changes, both systemic and local, to the development of portal vein thrombosis is debated. One of the hypotheses put forward on the genesis of portal vein thrombosis is as follows: certain bacterial translocations from the digestive tract, promoted by portal hypertension, contribute to endothelial activation resulting in the release of von Willebrand factor and factor VIII, as well as platelet activation and the coagulation cascade, which is dysregulated by cirrhosis and underlying changes in haemostatic balance. Inflammatory phenomena and NETosis may also be involved. Studies suggest that cirrhotic patients have lesions of the glycocalyx located in the portal area, which may be involved in the development of portal vein thrombosis. Patients with cirrhosis may benefit from the placement of a transjugular intrahepatic portosystemic shunt (TIPS). During the TIPS placement procedure, blood is drawn from the internal jugular vein and the portal vein, allowing for parallel biological analyses. The assumption of this study is that haemostasis and inflammation are disrupted differently at the systemic and portal levels in cirrhotic patients.",[25,165],[348,465,466,467,468,469,470,471,472,473],"portal hypertension","Transjugular Intrahepatic Portosystemic Shunt","Primary Hemostasis","Blood Coagulation","Fibrinolysis","Thromboinflammation","von Willebrand Factor","Endothelial Dysfunction","Portal Circulation",{"date":224,"type":36},{"date":476,"type":36},"2026-03-09",{"date":478,"type":20},"2027-06-09",{"name":480,"class":43},"Assistance Publique - Hôpitaux de Paris",{"id":482,"slug":483,"hasResults":12,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":487,"eligibilityCriteria":488,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":83,"enrollmentInfo":489,"targetDuration":4,"studyType":58,"phases":491,"briefSummary":493,"conditions":494,"keywords":495,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":504,"completionDateStruct":505,"leadSponsor":507,"locationsCount":4},"100633636","phase-3-can-aspirin-reduce-the-risk-of-hcc-in-cirrhosis-the-aspire-hcc-trial-100633636","NCT07529262","Can Aspirin Reduce the Risk of HCC in Cirrhosis: The AspiRe HCC Trial","Can Aspirin Reduce the Risk of Hepatocellular Carcinoma (HCC) in Participants With Cirrhosis: a Multicentre, Placebo-controlled Clinical Trial - The AspiRe HCC Trial","AspiRe HCC","Inclusion Criteria:\n\n* Provide written informed consent to participate in the trial according to ICH GCP (R3) and national\u002Flocal regulations.\n* Diagnosed with liver cirrhosis for at least 6 months\n* Has a current Child-Pugh score ≤6 (Child A - clinically and biochemically compensated cirrhosis)\n* Has been participating in ultrasound or non-ultrasound (computed tomography (CT) or magnetic resonance imaging (MRI)) based surveillance for at least 6 months prior to entry.\n* Has not had any focal lesions, other than haemangiomas, detected during the past 6 months.\n\nExclusion Criteria:\n\n* Any of the following:\n\n  * autoimmune liver disease.\n  * primary biliary cholangitis.\n  * primary sclerosing cholangitis.\n  * prior HCC\n  * alcohol consumption \\>3 standard drinks per day in men and 2 standard drinks per day in women.\n  * currently taking a nonsteroidal anti-inflammatory drug, anticoagulant drugs, non-vitamin K anticoagulant frugs, or other antiplatelet drugs, including aspirin, within the last 6 months.\n  * a known bleeding disorder\n  * a platelet count \\\u003C50 x 109\u002FL.\n  * known history or endoscopic evidence of high risk oesophageal (grade 2 or higher) or gastric varices or, a history of bleeding varices.\n  * chronic iron deficiency anaemia.\n  * a prior history of liver decompensation or liver transplantation.\n  * known peptic ulcer disease.\n  * chronic kidney disease with eGFR \\\u003C50ml\u002Fmin; a contraindication to aspirin.\n  * Any participant considered by the PI to be deemed unlikely to complete the study due to other comorbid conditions or poor compliance will also be excluded.\n\nPregnancy:\n\n* Whilst low dose aspirin is considered safe in pregnancy, male and female participants of child-bearing potential are recommended use effective contraception during this trial.\n* Any female participants who fall pregnant during the trial will be withdrawn if their treating obstetric doctor advises that you should do so.",{"count":490,"type":20},890,[492],"PHASE3","This clinical trial is testing whether taking a low dose aspirin tablet (100 mg) once a day can help prevent liver cancer (hepatocellular carcinoma, HCC) in people who have cirrhosis, which is severe scarring of the liver. People with cirrhosis have a higher risk of developing HCC. Currently, there is no approved treatment that prevents liver cancer in this group.\n\nResearch from around the world suggests that low dose aspirin might reduce the risk of liver cancer by up to half and is safe for people with cirrhosis. However, it is not yet approved for this purpose in Australia. A trial is needed to find out if aspirin really can prevent liver cancer in people with cirrhosis and is safe for these people to use.\n\n890 people from up to 7 hospitals across Australia will take part.\n\nParticipants will take medication daily for 4 years. They will be randomly allocated to either aspirin or a placebo (dummy pill).\n\nParticipants will continue to have their regular 6 monthly clinic visit with liver ultrasounds and blood tests as part of their normal care.\n\nIf at any time liver cancer is found, they will stop the trial.\n\nParticipants will also complete some extra tasks:\n\n* Record missed doses or other medications in a small diary.\n* Fill in two short quality of life surveys each year.\n* Return their medication and diary at their regular 6 monthly appointments.\n* In Western Australia only: they will be invited to give optional blood samples for future research.",[25],[496,497,498,499,500,267],"Hepatic","Cancer","Carcinoma","Hepatocellular","Liver","2026-04-13",{"date":503,"type":36},"2026-04-14",{"date":147,"type":20},{"date":506,"type":20},"2030-06-30",{"name":508,"class":43},"Curtin University",{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":396,"enrollmentInfo":516,"targetDuration":4,"studyType":58,"phases":518,"briefSummary":519,"conditions":520,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":527,"locationsCount":4},"100619642","phase-3-a-novel-extracorporeal-liver-support-therapy-in-alcf-and-to-evaluate-the-efficacy-of-dialive-20-a-liver-dialysis-device-100619642","NCT07347275","A Novel Extracorporeal Liver Support Therapy In ALCF and to Evaluate the Efficacy of DIALIVE 2.0, a Liver Dialysis Device.","A Multi-Centre, Randomised, Controlled Trial to Evaluate the Efficacy of DIALIVE 2.0, a Liver Dialysis Device, for the Treatment of Acute-on-Chronic Liver Failure (ACLF) A-TANGO Grade 2-4 Compared to Standard of Care (SoC)","Inclusion Criteria:\n\n* Adults aged 18-70 years, with a diagnosis of ACLF grade 2-4 (according to A-TANGO ACLF criteria, APPENDIX 1)\n* ACLF non-responsive to SoC for up to 48 hours prior to developing grade 2-4 ACLF.\n* Inclusion within 10 days from the onset of A-TANGO ACLF grade ≥ 2.\n\nExclusion Criteria:\n\n* A-TANGO ACLF grade ≥2 for more than 10 days prior to inclusion\n* Pregnancy\n* Co-infection with HIV and AIDS defining illness i.e. CD4+ T-cell count below 200 cells\u002FµL, a CD4+ T-cell percentage of total lymphocytes of less than 15%, or one of the defining illnesses such as PCP, Kaposi's sarcoma, CMV, Candidiasis etc.\n* Bacterial infection or sepsis unresponsive to treatment with antimicrobials for 48 hours indicated by (a) persistent pyrexia (b) rising white cell count, creactive protein and lactate (c) persistently positive cultures for bacteria or fungi and\u002For (d) worsening clinical state indicated by escalating requirement for fluid resuscitation, increasing vasopressors requirements or increasing organ support.\n* Invasive fungal infection (clinical or radiological evidence, not solely biomarker positivity such as BDG or galactomannan)\n* Acute or sub-acute liver failure in the absence of cirrhosis\n* Post-hepatectomy liver failure or primary non-function following transplantation\n* Previous liver transplant\n* Severe thrombocytopaenia (absolute platelet count \\\u003C20,000\u002Fmm3 at screening) or evidence of rapid decline in platelet count (\\> 50% reduction within the preceding 24 hrs)\n* INR \\>3.0, unless sustained correction for \\>24 hours following FFP\u002FPCC treatment\n* Severe disseminated intravascular coagulopathy (DIC)\n* Persistent haemodynamic instability as defined by:\n\n  (i) Norepinephrine(NE) dose \\>0.5µg\u002Fkg\u002Fmin, or, (ii) If a second pressor is used, a composite Norepinephrine equivalence index (NEEI) of dose \\>0.5µg\u002Fkg\u002Fmin (iii) Arterial lactate level \\>4mmol\u002FL despite 24 hours of adequate fluid resuscitation and pressor therapy\n* Severe respiratory failure: PaO2\u002FFiO2 (P\u002FF) ≤ 200 mmHg or 27kPa\n* Established on renal replacement therapy for longer than 24 hours prior to inclusion\n* A-TANGO WCC ACLF score \\>64 (APPENDIX 1)\n* Significant and\u002For uncontrolled bleeding (participants can be enrolled 48 hours after bleeding is controlled)\n* Active or prior history of non hepatic malignancy unless adequately treated or in complete remission for five or more years\n* HCC outside of Milan criteria.\n* Acute, extensive, portal vein thrombosis extending to and occluding superior mesenteric vein\n* Major systemic illness, aside from liver disease, that in the opinion of the investigator would preclude the participant from participating in the study (e.g. coronary artery disease, cerebrovascular disease, chronic pulmonary disease, chronic kidney disease, serious psychiatric disease)\n* Pre-existing chronic kidney disease (CKD) defined as eGFR (estimated glomerular filtration rate) \\\u003C30 mL\u002Fmin for 3 months or longer prior to screening\n* Severe frailty (Clinical Frailty Scale, CFS\\>5)\n* Severe malnourishment (BMI\\\u003C18)\n* Participants not considered appropriate for full active treatment including organ support\n* Participants who have a \"do not attempt cardio-pulmonary resuscitation\" order in place\n* Any participant who has received an investigational drug or device within 30 days, or who is scheduled to receive another investigational drug or device during the course of the study (concomitant observational studies are allowed)\n* Uncontrolled seizures\n* Evidence of new intracranial pathology such as cerebral hemorrhage or infarction.\n* Participants diagnosed with Creutzfeldt-Jakob disease.\n* Participants unable to consent for themselves, unless a legal representative\u002Fconsultee is appointed and approved as dictated by local and national legislation.\n* Known allergy to heparin, or type II thrombocytopaenia caused by heparin (HIT syndrome type II).\n* In the opinion of the investigator, recruitment to the the study would be unsafe for the participant.",{"count":517,"type":20},72,[492],"This study is intended to demonstrate the efficacy and safety of the DIALIVE Liver Dialysis Device when incorporated into the standard management plan for participants with A-TANGO ACLF grade 2-4.\n\nA total of 72 evaluable participants, aged 18-70, will be enrolled in up to 12 clinical centres in the United Kingdom. Participants must have a history of liver cirrhosis and a deterioration within four weeks due to a precipitating event, leading to A-TANGO ACLF grade 2-4. Multicenter, individually randomised, controlled, open-label, parallel group trial using double-arm design. The control group will receive SoC for participants with ACLF. The DIALIVE 2.0 treatment group will receive SoC with the addition of up to 7 (seven) daily DIALIVE 2.0 treatment sessions within the 10-day treatment window. Seventy-two participants with ACLF (60% A-TANGO ACLF grade 2 at randomisation, and 40% A-TANGO ACLF grade 3 \\& 4 at randomisation) will be randomised 1:1 to receive either SoC or SoC + DIALIVE 2.0. This allows for 5% loss due to drop-out, and 5% censoring due to liver transplantation within 28 days. All randomised participants will be included in the intention to treat (ITT) analysis while all participants that receive at least one treatment cycle will be used for the safety population. For each participant, the study duration will be up to 105 days (screening: 5 days; treatment up to 10 days; follow up 90 days).\n\nThe total study duration is estimated to be approximately 18 months from screening of first participant until study completion of the last participant.",[521,25],"Acute-on-Chronic Liver Failure (ACLF)","2026-04-08",{"date":503,"type":36},{"date":525,"type":20},"2026-05",{"date":307,"type":20},{"name":528,"class":99},"Yaqrit Ltd",{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":536,"enrollmentInfo":537,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":539,"conditions":540,"keywords":544,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":551,"completionDateStruct":552,"leadSponsor":553,"locationsCount":4},"100631554","heart-problems-in-children-with-chronic-liver-disease-100631554","NCT07502196","Heart Problems in Children With Chronic Liver Disease","Assessment of Cardiac Problems in Children With Chronic Liver Disease","Inclusion Criteria:\n\n* All patients below 18 years who diagnosed with chronic liver disease.\n\nExclusion Criteria:\n\n* All patients known to have congenital heart disease or previous cardiac disease.","17 Years",{"count":538,"type":20},60,"Chronic liver disease (CLD) in children can sometimes lead to complications in other parts of the body, including the heart. The primary purpose of this observational study is to assess the presence and type of cardiac problems in children who have been diagnosed with chronic liver disease.\n\nResearchers will observe children under the age of 18 who are receiving care at the gastroenterology and hepatology unit at Assiut University Children Hospital. Participants will undergo standard medical evaluations to check both their liver and heart health.\n\nThese evaluations include:\n\n* A detailed medical history and thorough physical examination\n* Routine blood tests to check liver function, kidney function, coagulation, and electrolytes\n* Abdominal imaging, such as an ultrasound, to look at the liver.\n* An electrocardiogram (ECG) to check the heart's electrical activity and rhythm, including measuring the QTc interval.\n* An echocardiogram to look at the structure of the heart and check how well its chambers and valves are functioning.\n\nThe study aims to identify specific heart conditions that can be associated with severe liver disease, such as portopulmonary hypertension, cirrhotic cardiomyopathy (changes in the heart muscle's function), and electrical repolarization abnormalities. Children who already have known congenital heart disease or a history of other heart problems will not be included in the study.",[295,25,541,542,543],"Cardiac Abnormalities","Portopulmonary Hypertension","Cirrhotic Cardiomyopathy",[545,25,546,542,543,547],"Chronic Liver Disease","Cardiac Problems","Cardiac Repolarization Abnormalities","2026-03-25",{"date":550,"type":36},"2026-03-30",{"date":305,"type":20},{"date":307,"type":20},{"name":309,"class":43},{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":560,"eligibilityCriteria":561,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":562,"targetDuration":4,"studyType":58,"phases":564,"briefSummary":565,"conditions":566,"keywords":572,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":578,"lastUpdatePostDateStruct":579,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":44},"100630837","multiparametric-ultrasound-for-the-noninvasive-diagnosis-of-porto-sinusoidal-vascular-liver-disorder-100630837","NCT07492862","Multiparametric Ultrasound for the Noninvasive Diagnosis of Porto-sinusoidal Vascular Liver Disorder","Explorative Study for the Application of Dynamic Contrast-enhanced Ultrasound for the Noninvasive Diagnosis of Porto-sinusoidal Vascular Liver Disorder","CEUS-PSVD","Inclusion criteria - PSVD group\n\n* Histologically confirmed diagnosis of porto-sinusoidal vascular disease (PSVD);\n* Presence of clinically significant portal hypertension, evidenced by at least one specific sign of portal hypertension (e.g., imaging evidence of collateral circulation or porto-systemic shunts, endoscopic evidence of esophageal or gastric varices, or history of gastrointestinal variceal bleeding);\n* Age ≥ 18 years;\n* Ability to understand the study information and provide written informed consent;\n\nInclusion criteria - Cirrhosis group\n\n* Diagnosis of liver cirrhosis confirmed by liver histology or, alternatively, by compatible findings on imaging, laboratory tests, and physical examination together with a positive history for at least one known cause of chronic liver disease;\n* Presence of clinically significant portal hypertension, evidenced by at least one specific sign of portal hypertension (e.g., imaging evidence of collateral circulation or porto-systemic shunts, endoscopic evidence of esophageal or gastric varices, or history of gastrointestinal variceal bleeding);\n* Age ≥ 18 years;\n* Ability to understand the study information and provide written informed consent.\n\nExclusion criteria - PSVD group (cases)\n\n* Presence of other causes of portal hypertension, including but not limited to: history of bone marrow transplantation, Budd-Chiari syndrome or hepatic venous outflow obstruction, hepatic schistosomiasis, Abernethy malformation, hereditary hemorrhagic telangiectasia, sarcoidosis, congenital hepatic fibrosis, or chronic cholestatic liver diseases;\n* Presence of portal, spleno-mesenteric, or hepatic vein thrombosis;\n* Prior hepatic or splenic surgery;\n* Presence of primary or secondary malignant liver tumors;\n* Presence of a transjugular intrahepatic portosystemic shunt (TIPS) device;\n* Congenital anomalies of the liver or biliary tract;\n* History of heart failure;\n* Contraindications to administration of SonoVue (sulfur hexafluoride microbubbles), including: prior allergic reaction to the active substance or any excipients, known right-to-left shunts, severe pulmonary hypertension (pulmonary artery pressure \\> 90 mmHg), uncontrolled systemic hypertension, or adult respiratory distress syndrome;\n* Inadequate sonographic visualization of the right hepatic lobe;\n* Pregnancy.\n\nExclusion criteria - Cirrhosis group\n\n* Decompensated cirrhosis or Child-Pugh class C;\n* Cryptogenic cirrhosis;\n* Presence of other causes of portal hypertension (same list as for PSVD exclusions: history of bone marrow transplantation, Budd-Chiari syndrome or hepatic venous outflow obstruction, hepatic schistosomiasis, Abernethy malformation, hereditary hemorrhagic telangiectasia, sarcoidosis, congenital hepatic fibrosis, chronic cholestatic diseases);\n* Presence of portal, spleno-mesenteric, or hepatic vein thrombosis;\n* Prior hepatic or splenic surgery;\n* Presence of primary or secondary malignant liver tumors;\n* Presence of a transjugular intrahepatic portosystemic shunt (TIPS) device;\n* Congenital anomalies of the liver or biliary tract;\n* History of heart failure;\n* Contraindications to administration of SonoVue (sulfur hexafluoride microbubbles), including: prior allergic reaction to the active substance or any excipients, known right-to-left shunts, severe pulmonary hypertension (pulmonary artery pressure \\> 90 mmHg), uncontrolled systemic hypertension, or adult respiratory distress syndrome;\n* Inadequate sonographic visualization of the right hepatic lobe;\n* Pregnancy.",{"count":563,"type":20},100,[112],"Porto-sinusoidal vascular disease (PSVD) is a rare clinical entity characterized by significant portal hypertension in the absence of cirrhosis on liver histology, which may or may not show specific alterations of the portal vein, sinusoids, or hepatic lobular architecture. Currently, diagnosis of this condition necessarily requires a liver biopsy and, despite some differences detected on imaging studies-and particularly on liver and spleen elastography-PSVD remains indistinguishable from cirrhosis using non-invasive tests.\n\nContrast-enhanced ultrasound (CEUS) is an easy-to-perform, repeatable, and cost-effective examination that enables real-time assessment of parenchymal or focal liver lesion perfusion. Moreover, the application of dynamic contrast-enhanced ultrasound (DCE-US-i.e., contrast-enhanced ultrasound followed by quantitative perfusion analysis using dedicated software, such as the VueBox Software that will be used in this study) allows integration of CEUS qualitative assessment with quantitative evaluation of tissue perfusion through analysis of time-intensity curves generated during contrast transit. From this analysis, several perfusion-related parameters can be derived (for example, peak enhancement, time to peak, or area under the curve), which have already proven useful in improving differential diagnosis of focal liver lesions and in predicting treatment response and systemic therapy outcomes.\n\nTo date, the use of DCE-US for the diagnosis of PSVD has not yet been described; however, based on the underlying histological alterations associated with this disease, it is reasonable to hypothesize that parameters obtained with this technique in the liver parenchyma of patients with PSVD may differ from those measured in patients with liver cirrhosis. The aim of the present project is to apply DCE-US in patients with PSVD and in patients with cirrhosis to evaluate potential significant differences in perfusion parameters, and to assess the feasibility of a non-invasive differential diagnosis between the two conditions using this technique in combination with elastography and bidimensional ultrasound data to develop a multiparametric diagnostic score.",[567,25,568,569,570,571],"Porto-sinusoidal Vascular Liver Disorder","Portal Hypertension, Noncirrhotic","Portal Hypertension Related to Cirrhosis","Ultrasound Elastography","Contrast-enhanced Ultrasound",[573,348,574,575,576,577],"porto-sinusoidal vascular liver disorder","liver ultrasound","ultrasound elastography","dynamic contrast-enhanced ultrasound","chronic liver disease","2026-03-20",{"date":548,"type":36},{"date":581,"type":20},"2026-03",{"date":583,"type":20},"2028-12",{"name":585,"class":43},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":587,"slug":588,"hasResults":12,"nctId":589,"briefTitle":590,"officialTitle":591,"acronym":592,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":594,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":596,"conditions":597,"keywords":599,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":44},"100568389","utilizing-of-physiological-parameters-predict-the-prognosis-of-cirrhotic-patients-with-gastrointestinal-bleeding-100568389","NCT06680583","Utilizing of Physiological Parameters Predict the Prognosis of Cirrhotic Patients With Gastrointestinal Bleeding","Utilizing of Physiological Parameters And Derived Indices to Predict The Prognosis of Cirrhotic Patients With Gastrointestinal Bleeding","SI","Inclusion Criteria: cirrhosis with gastrointestinal bleeding -\n\nExclusion Criteria: no complete medical record and trauma patient\n\n\\-",{"count":595,"type":20},150,"Can physiological indicators such as quick Sequential Organ Failure Assessment , Shock Index, and its derived indicators such as Modified Shock Index , Age Shock Index and Respiratory Adjusted Shock Index accurately predict the prognosis of cirrhosis patients with gastrointestinal bleeding? To explore the improvement of emergency and critical care patient management.",[25,598],"Gastrointestinal Bleeding",[600,601,602,603],"cirrhosis","gastrointestinal bleeding","physical indicator","shock index","2026-03-16",{"date":606,"type":36},"2026-03-17",{"date":608,"type":36},"2024-11-01",{"date":610,"type":20},"2027-03-11",{"name":612,"class":43},"St. Martin De Porress Hospital",{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":618,"acronym":4,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":83,"enrollmentInfo":620,"targetDuration":4,"studyType":58,"phases":622,"briefSummary":624,"conditions":625,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":628,"completionDateStruct":630,"leadSponsor":632,"locationsCount":44},"100629253","phase-1-safety-evaluation-of-msc-based-therapy-for-liver-cihcrosis-treatment-100629253","NCT07472270","Safety Evaluation of MSC-based Therapy for Liver Cihcrosis Treatment","Phase 1 Clinical Trial: Evaluation of the Safety and Preliminary Efficacy of Umbilical Cord-Derived Mesenchymal Stem Cell Extracellular Vesicle Therapy in the Treatment of Liver Cirrhosis","Inclusion Criteria:\n\n* Liver cirrhosis due to alcohol-related liver disease or chronic hepatitis B or C\n* Child-Pugh score 7-12\n* Alcohol-related cirrhosis: abstinent from alcohol ≥ 3 months\n* HBV\u002FHCV-related cirrhosis: viral disease controlled according to standard clinical criteria\n* Written informed consent provided\n\nExclusion Criteria:\n\n* Significant renal dysfunction or coagulation abnormalities\n* Liver cirrhosis of unknown etiology\n* Current or suspected hepatocellular carcinoma or history of malignancy\n* Portal vein thrombosis\n* Pregnancy, breastfeeding, or inadequate contraception\n* Severe renal, respiratory, cardiovascular, infectious, autoimmune, metabolic, or neurological disorders that may interfere with study participation\n* Refractory ascites at screening\n* Use of known hepatotoxic medications within a clinically relevant period\n* Coinfection with HIV, tuberculosis, or other causes of chronic liver disease",{"count":621,"type":20},12,[623],"PHASE1","This study Phase 1 clinical trial aimed to evaluate the safety and preliminary efficacy of intravenously administered extracellular vesicles derived from umbilical cord mesenchymal stem cells (UC-MSC-EVs; VinEV-3) in patients with liver cirrhosis. The trial uses a rolling six dose-escalation design, enrolling up to 12 adult patients (18-75 years) with Child-Pugh scores of 7-12.\n\nThe results of this study are expected to provide initial clinical evidence supporting the safety and potential therapeutic role of UC-MSC-EVs as a novel cell-free treatment approach for liver cirrhosis.",[25],"2026-03-13",{"date":604,"type":36},{"date":629,"type":20},"2026-03-15",{"date":631,"type":20},"2026-12-31",{"name":633,"class":43},"Vinmec Research Institute of Stem Cell and Gene Technology",{"id":635,"slug":636,"hasResults":12,"nctId":637,"briefTitle":638,"officialTitle":639,"acronym":640,"eligibilityCriteria":641,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":642,"targetDuration":4,"studyType":58,"phases":644,"briefSummary":645,"conditions":646,"keywords":648,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":654,"lastUpdatePostDateStruct":655,"startDateStruct":656,"completionDateStruct":658,"leadSponsor":659,"locationsCount":44},"100629120","fiber-optic-navigation-during-tips-creation-a-prospective-pilot-study-100629120","NCT07470515","Fiber-Optic Navigation During TIPS Creation: A Prospective Pilot Study","Fiber-Optic Navigation During Transjugular Intrahepatic Portosystemic Shunt Creation: A Prospective Pilot Study Evaluating Procedural Parameters","FLIGHT","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Clinical indication for transjugular intrahepatic portosystemic shunt (TIPS) creation according to standard clinical practice (e.g., refractory ascites or variceal bleeding)\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Inability or unwillingness to provide informed consent\n* Pregnancy or breastfeeding\n* Absolute contraindications to TIPS according to current clinical standards (e.g., severe right heart failure, uncontrolled systemic infection)\n* Participation in another clinical study that may interfere with the results of this study",{"count":643,"type":20},30,[112],"Transjugular intrahepatic portosystemic shunt (TIPS) creation is an established minimally invasive treatment for complications of portal hypertension such as refractory ascites and variceal bleeding. A technically challenging step of the procedure is the puncture of the portal vein from the hepatic vein, which is usually performed under fluoroscopic guidance and may require multiple puncture attempts.\n\nThis prospective pilot study evaluates the use of fiber-optic navigation technology during TIPS creation. The system allows real-time three-dimensional visualization of guidewires and catheters and may improve spatial orientation during the procedure.\n\nApproximately 30 patients with a clinical indication for TIPS placement will be included. The study will assess procedural parameters such as the number of puncture attempts, fluoroscopy time, radiation exposure, procedure duration, technical success, and complications.\n\nThe results may help to improve procedural efficiency and radiation safety during TIPS interventions.",[25,647,292,165],"Refractory Ascites",[190,165,649,650,651,652,653],"Interventional Radiology","Fiber-Optic Navigation","Image-Guided Intervention","Endovascular Navigation","Radiation Reduction","2026-03-10",{"date":626,"type":36},{"date":657,"type":20},"2027-01",{"date":583,"type":20},{"name":660,"class":43},"Medical University Innsbruck",{"id":662,"slug":663,"hasResults":12,"nctId":664,"briefTitle":665,"officialTitle":666,"acronym":4,"eligibilityCriteria":667,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":83,"enrollmentInfo":668,"targetDuration":4,"studyType":58,"phases":670,"briefSummary":671,"conditions":672,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":673,"lastUpdatePostDateStruct":674,"startDateStruct":676,"completionDateStruct":678,"leadSponsor":680,"locationsCount":44},"100628732","carvedilol-and-midodrine-versus-carvedilol-alone-in-preventing-early-rebleed-in-patients-with-cirrhosis-100628732","NCT07465471","Carvedilol and Midodrine Versus Carvedilol Alone in Preventing Early Rebleed in Patients With Cirrhosis.","Carvedilol and Midodrine Versus Carvedilol Alone in Preventing Early Rebleed in Patients With Cirrhosis: A Randomized Controlled Trial.","Inclusion Criteria:\n\n1. Consecutive patients of cirrhosis with high-risk acute variceal bleed (Child-Pugh class B \\> 7 with active bleeding at initial endoscopy or Child-Pugh class C \\\u003C 14 points).\n\nExclusion Criteria:\n\n1. Age less than 18 years or \\> 75 years.\n2. HR \\\u003C 60\u002F min and BP \\\u003C 100\u002F60 mm Hg\n3. Child-Pugh's score \\\u003C8 and \\>13.\n4. MELD score \\>30 and serum lactate \\>12mmol\u002FL.\n5. Refractory variceal bleed.\n6. Preemptive TIPS or previous Porto-systemic shunt or TIPS.\n7. Non-selective Beta blocker\u002Fcarvedilol \u002F midodrine treatment in last 5 days.\n8. Acute kidney injury - HRS.\n9. Uncontrolled Hypertension (BP \\> 140\u002F90 mmHg), heart block, congestive heart failure.\n10. Contraindication to NSBB (HR\\\u003C60\u002Fmin, BP\\\u003C90\u002F60mmHg, bronchial asthma).\n11. Hepatocellular carcinoma (outside Milan criteria), extrahepatic malignancy.\n12. Pregnant women.\n13. Bleeding from isolated gastric or ectopic varices.",{"count":669,"type":20},210,[112],"Acute variceal bleeding (AVB) in cirrhosis occurs as a result of portal hypertension and carries a 6-week mortality rate of approximately 10-20%. Standard management includes a restrictive transfusion approach, vasoactive therapy, prophylactic antibiotics, and endoscopic band ligation. Despite this, early rebleeding within the first 5 days still occurs in about 10-20% of patients, and individuals at particularly high risk may benefit from pre-emptive TIPS. However, its real-world use remains limited; one study reported that only 6.7% of eligible patients actually underwent pre-emptive TIPS, primarily due to logistical challenges and limited interventional radiology availability for early, non-emergent TIPS procedures.\n\nMidodrine, an oral and fast-acting selective α1-adrenergic agonist, has been shown to enhance the effectiveness of nonselective beta-blockers like propranolol by allowing higher tolerated doses and achieving greater reductions in portal pressure (HVPG), thereby reducing the risk of initial variceal bleeding. However, no studies have evaluated the combination of midodrine with carvedilol-currently a preferred agent-versus carvedilol alone in patients at high risk of rebleeding.\n\nTo address this gap, we propose a study comparing carvedilol plus midodrine with carvedilol alone for preventing early rebleeding in cirrhotic patients. Individuals with cirrhosis (Child-Pugh 8-13) presenting with hematemesis will be enrolled, stabilized according to APASL guidelines, and after 48 hours randomized to either combined midodrine-carvedilol therapy or carvedilol alone. Participants will be followed for 6 weeks to assess the incidence of early rebleeding.",[25],"2026-03-06",{"date":675,"type":36},"2026-03-12",{"date":677,"type":20},"2026-03-01",{"date":679,"type":20},"2027-09-30",{"name":681,"class":43},"Institute of Liver and Biliary Sciences, India"]